María Del Carmen Vennera1,2,3, Antonio Valero4,5,6, Estefany Uría7, Carles Forné7, César Picado4,5,6. 1. Department of Pneumology and Respiratory Allergy, Hospital Clinic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. cvennera@clinic.ub.es. 2. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. cvennera@clinic.ub.es. 3. Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. cvennera@clinic.ub.es. 4. Department of Pneumology and Respiratory Allergy, Hospital Clinic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain. 5. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 6. Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 7. Department of Health Economics and Outcome Research, Oblikue Consulting S.L., Barcelona, Spain.
Abstract
BACKGROUND AND OBJECTIVE: Omalizumab is a humanized monoclonal antibody that targets circulating immunoglobulin E molecules to treat severe uncontrolled asthma. The aim of this study was to determine the cost effectiveness of omalizumab compared with standard treatment for the control of severe persistent asthma according to data from patients treated in a specialized asthma unit. METHODS: This was an observational, retrospective, single-center study in the setting of the Pulmonology and Respiratory Allergy Service, Thorax Institute, Hospital Clínic de Barcelona, Barcelona, Spain. Data were collected by review of medical records of 86 uncontrolled severe persistent asthma patients treated with omalizumab from January 2005 to April 2014. Effectiveness was assessed by the reduction in asthma exacerbations and 3-point increases in the Asthma Control Test (ACT) score. The economic evaluation was performed from the societal perspective, including direct health costs (resource use and drug treatments) and indirect costs (disease impact on labor productivity) in 2016 Euros. The time horizon was 12 months before and after the initiation of treatment with omalizumab. Results were expressed using the incremental cost-effectiveness ratio (ICER). RESULTS: Taking into account only direct costs, the ICERs were €1487.46 (95 % confidence interval [CI] 1241.21-1778.34) per exacerbation avoided and €5425.13 (95 % CI 4539.30-6551.03) per 3-point increase in the ACT. When indirect costs were included, the ICERs were €1130.93 (95 % CI 909.08-1392.86) per exacerbation avoided, and €4124.79 (95 % CI 3281.69-5186.73) per 3-point increase in the ACT. CONCLUSIONS: The results of this study confirm the effectiveness of the addition of omalizumab to standard therapy in patients with uncontrolled severe persistent asthma.
BACKGROUND AND OBJECTIVE:Omalizumab is a humanized monoclonal antibody that targets circulating immunoglobulin E molecules to treat severe uncontrolled asthma. The aim of this study was to determine the cost effectiveness of omalizumab compared with standard treatment for the control of severe persistent asthma according to data from patients treated in a specialized asthma unit. METHODS: This was an observational, retrospective, single-center study in the setting of the Pulmonology and Respiratory Allergy Service, Thorax Institute, Hospital Clínic de Barcelona, Barcelona, Spain. Data were collected by review of medical records of 86 uncontrolled severe persistent asthmapatients treated with omalizumab from January 2005 to April 2014. Effectiveness was assessed by the reduction in asthma exacerbations and 3-point increases in the Asthma Control Test (ACT) score. The economic evaluation was performed from the societal perspective, including direct health costs (resource use and drug treatments) and indirect costs (disease impact on labor productivity) in 2016 Euros. The time horizon was 12 months before and after the initiation of treatment with omalizumab. Results were expressed using the incremental cost-effectiveness ratio (ICER). RESULTS: Taking into account only direct costs, the ICERs were €1487.46 (95 % confidence interval [CI] 1241.21-1778.34) per exacerbation avoided and €5425.13 (95 % CI 4539.30-6551.03) per 3-point increase in the ACT. When indirect costs were included, the ICERs were €1130.93 (95 % CI 909.08-1392.86) per exacerbation avoided, and €4124.79 (95 % CI 3281.69-5186.73) per 3-point increase in the ACT. CONCLUSIONS: The results of this study confirm the effectiveness of the addition of omalizumab to standard therapy in patients with uncontrolled severe persistent asthma.
Authors: María Del Carmen Vennera; Luis Pérez De Llano; Santiago Bardagí; Pilar Ausin; Carles Sanjuas; Héctor González; José A Gullón; Eva Martínez-Moragón; José A Carretero; Elisabet Vera; Juan F Medina; Francisco J Alvarez; Luis M Entrenas; Alicia Padilla; Rosa Irigaray; César Picado Journal: J Asthma Date: 2012-03-23 Impact factor: 2.515
Authors: M Cazzola; G Camiciottoli; M Bonavia; C Gulotta; A Ravazzi; A Alessandrini; M F Caiaffa; A Berra; P Schino; P L Di Napoli; R Maselli; G Pelaia; E Bucchioni; P L Paggiaro; L Macchia Journal: Respir Med Date: 2010-05-18 Impact factor: 3.415
Authors: S T Holgate; A G Chuchalin; J Hébert; J Lötvall; G B Persson; K F Chung; J Bousquet; H A Kerstjens; H Fox; J Thirlwell; G Della Cioppa Journal: Clin Exp Allergy Date: 2004-04 Impact factor: 5.018
Authors: R Brett McQueen; Danielle N Sheehan; Melanie D Whittington; Job F M van Boven; Jonathan D Campbell Journal: Pharmacoeconomics Date: 2018-08 Impact factor: 4.981
Authors: Giorgio Walter Canonica; Giorgio Lorenzo Colombo; Paola Rogliani; Pierachille Santus; Claudia Pitotti; Sergio Di Matteo; Chiara Martinotti; Giacomo Matteo Bruno Journal: Risk Manag Healthc Policy Date: 2020-01-22
Authors: Luis Manuel Entrenas Costa; Francisco Casas-Maldonado; José Gregorio Soto Campos; Alicia Padilla-Galo; Alberto Levy; Francisco Javier Álvarez Gutiérrez; Ana P Gómez-Bastero Fernández; Concepción Morales-García; Rocío Gallego Domínguez; Gustavo Villegas Sánchez; Luis Mateos Caballero; Antonio Pereira-Vega; Cayo García Polo; Gerardo Pérez Chica; Juan José Martín Villasclaras Journal: Pharmacoecon Open Date: 2019-09
Authors: A Padilla-Galo; A J García-Ruiz; R Ch Levy Abitbol; C Olveira; F Rivas-Ruiz; N García-Agua Soler; M Pérez Morales; B Valencia Azcona; B Tortajada-Goitia; I Moya-Carmona; A Levy-Naon Journal: Respir Res Date: 2021-05-27